🎙️ In a recent OncLive On Air podcast, David Morris, MD, FACS, and Alan Bryce, MD, discuss the FDA approval of rucaparib for patients with BRCA mutation–associated mCRPC.
🔗 Listen to the podcast: www.onclive.com/view/fda-app...
#ProstateCancer #mCRPC #PARPInhibitors #PrecisionOncology #Oncology

Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer - Molecular Biomedicine African American men experience markedly higher prostate cancer incidence and mortality yet remain underrepresented in genomic studies aimed at identifying ancestry-associated molecular drivers of dis...

#Research
Circulating cell-free DNA (#cfDNA) profiling reveals ancestry-dependent genetic variation in #metastatic prostate cancer (#PC) doi.org/10.1186/s435...
Studied by researchers from Indiana University School of Medicine

#GeneticVariations #SomaticMutations #profiling #MCRPC

Lutetium Lu 177 Vipivotide Tetraxetan Remains Effective After Sipuleucel-T in mCRPC | OncLive Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

Real-world data show lutetium Lu 177 vipivotide tetraxetan maintains strong activity after sipuleucel-T, with median OS ~19.8 months and robust PSA responses #ProstateCancer #GUonc #mCRPC #RadioligandTherapy #Oncology
Read more ➡️ www.onclive.com/view/lutetiu...

Dr Jason Efsthathiou, presents PEACE-3 data: Adding Radium-223 to enzalutamide prolongs rPFS (19.4 vs 16.4 mo, HR 0.69) in #mCRPC with bone metastases. Research from Dr Enrique Gallardo.

Read the review and watch the full interview at: ➡️ https://bit.ly/4rNUPUK

#MedEd #OncTwitter #ProstateCancer

Metformin effects on renal function in mCRPC during PSMA radiopharmaceutical therapy (RPT): A retrospective analysis. 203Background: Preclinical research indicates that metformin may mitigate renal accumulation of lutetium-177-labeled PSMA radioligands in metastatic castration-resistant prostate cancer (mCRPC) by inh...

Check out our latest findings on #Metformin effects on renal function in #mCRPC during #PSMA radiopharmaceutical therapy @ascocancer.bsky.social #GU26

ascopubs.org/doi/abs/10.1...

@ascopost.bsky.social

Dr. Fred Saad presents #Trillium 225Ac-PSMA in #mCRPC phase 1 study

Substantial amount of dry mouth observed including 30% grade 2.

@ascocancer.bsky.social
#GU26

Dr. Fred Saad presents #Trillium 225Ac-PSMA in #mCRPC phase 1 study

Substantial amount of dry mouth observed including 30% grade 2.

@asco #GU26

📢 PEACE‑3 final results: adding radium‑223 to enzalutamide reduces risk of death by 24% in men with #mCRPC and bone metastases.

Results presented at ASCO @ascocancer.bsky.social #GU26 and published in Annals of Oncology.

🔗 Full press release: www.eortc.org/blog/2026/02...

#CancerResearch #PEACE3

That wraps up our live coverage of #GU26 sessions on #mCRPC!
From PEACE‑3 to BRCAAway, today’s discussions highlighted how combination strategies are reshaping overall survival in #mCRPC
For more congress coverage, visit the Prostate Cancer Nexus on Medthority

ow.ly/yCG750YmtgI

Key takeaways from BRCAAway:
🔹 A + O showed longest OS (46.2 mo)
🔹 Strongest 24‑ & 36‑mo OS landmarks 📈
🔹 AEs manageable; A + O maintained acceptable tolerability
🔹 Supports continued evaluation of PARPi + ABI in DDR‑mutated mCRPC
#GU26 #mCRPC #ProstateCancer #Oncology

Dr. Hussain presents OS results from the BRCAAway trial in first‑line #mCRPC with DDR defects:
🔹 Abiraterone, olaparib, or the combination in BRCA1/2/ATM
🔹 Median OS longest in Arm 3 (A+O): 46.2 mo
🔹 Arm 3 showed highest 24 & 36‑mo OS 📊

#GU26 #ProstateCancer #Oncology

What’s next for overall survival optimization in #mCRPC?
Following the PEACE‑3 final OS results with enzalutamide + radium‑223 from Enrique Gallardo, the conversation continues with Maha HA Hussain and the BRCAAway OS data at #GU26.

🗝 Key takeaway points from PEACE‑3:
📈 ENZA + 6 cycles Rad‑223 improves OS
⚠️ No new safety signals; moderate AE increase
💊 “ENZA + Rad‑223 (with BPA) is an option in first‑line mCRPC with bone metastases”

#GU26 #Oncology #MedEd #mCRPC #ProstateCancer #MedSky

Dr. Gallardo shares final data from PEACE‑3 (Enzalutamide ± Radium‑223) in mCRPC with bone mets:
🔹 Significant OS benefit with ENZA + Rad‑223
🔹 rPFS improvement confirmed 📈
🔹 Moderate ↑ in AEs

#GU26 #mCRPC #ProstateCancer #Oncology

How have combination strategies reshaping overall survival in #mCRPC?

Join our #GU26 coverage as Enrique Gallardo and Maha HA Hussain discuss the latest overall survival results from the EORTC 1333/PEACE‑3 and BRCAAway trials.
#ProstateCancer #Oncology #OncTwitter #MedEd #MedSky

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need.
🔗 Full article: buff.ly/9fa08rG
#ProstateCancer #mCRPC #PARPInhibitors #Oncology

Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting Androgen receptor-targeted agents and docetaxel are increasingly being used earlier in the disease course in men with metastatic prostate cancer. So what are the options once castration resistance…

Androgen receptor-targeted agents and docetaxel are increasingly being used earlier in the disease course in men with metastatic #ProstateCancer.

So what are the options once castration resistance develops?

👉 buff.ly/XYHXJvx

#mCRPC #OncSky

New research from Dr. Samir Zaidi with Dr. Michael Morris @mskcancercenter.bsky.social shows #PSMA expression can vary in #mCRPC, even in tumors that appear PSMA+ on imaging. Combining PSMA scans with blood-based biomarkers may help inform treatment decision–making.
aacrjournals.org/clincancerre...

Docetaxel rechallenge improved overall survival compared with switching to cabazitaxel, for patients with chemonaïve #mCRPC who did not experience progression during prior treatment with docetaxel. From @jamanetworkopen.com.

Read more here: ➡️ https://bit.ly/3NGNEyj

#prostatecancer #pcsm

Only 1 month to go until #GU2026! Get ready with a quick recap on key #ProstateCancer highlights from #GU2025 on Medthority, including expert insights on a new treatment option for HRR-deficient #mCRPC and our posters round-up #MedSky #MedEd #OncSky

ow.ly/Ytna50Y4UVE

▪️ ASCO Living Guidelines are continuously reviewed and regularly updated by experts to reflect emerging evidence.

🔗 Read more: bit.ly/ONCOnews21J-01

#ONCOnews #OncoAlert #OncEd #ProstateCancer #ASCOGuidelines #mCRPC #GenitourinaryCancer

Pasritamig (JNJ-78278343): A Next-Generation T-Cell Engager for Metastatic Castration-Resistant Prostate Cancer - OncoDaily Pasritamig (JNJ-78278343) is a KLK2×CD3 bispecific antibody for mCRPC, showing early efficacy with manageable CRS and outpatient-friendly dosing.

Pasritamig (JNJ-78278343): A Next-Generation T-Cell Engager for Metastatic Castration-Resistant Prostate Cancer

oncodaily.com/drugs/pasrit...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ProstateCancer #mCRPC

✨ Nueva aprobación en China: #Deutenzalutamida (#Hainaan).
👨‍⚕️ Diseñada para adultos con mCRPC después de abiraterona y quimio..
📎 Más información: dengyuemed.com/product/hain...
📧 info@dengyuemed.com
#FármacoInnovador #mCRPC #CPRCM #CáncerResistente #CáncerAvanzado #DengYueMedicinasEnHongKong

📝Access mCRPC treatment guidance in seconds with ONCOassist

#mCRPC #ProstateCancer #OncologyTools #CancerCare #ClinicalOncology #DigitalHealth #OncologyApp #AdvancedProstateCancer #oncologytools

Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration‐Resistant Prostate Cancer (mCRPC): A Phase Ib Trial Metastatic castration-resistant prostate cancer (mCRPC) remains challenging. This Phase Ib trial tested chidamide, a selective HDAC inhibitor, plus abiraterone in 18 patients. The regimen was well to...

#Article in #MedComm
Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase Ib Trial doi.org/10.1002/mco2...
#Clinicaltrial #EpigeneticRegulation #HistoneDeacetylase #mCRPC

As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

#GSK #oncology #Blenrep #ADC #antibodydrugconjugates #prostatecancercandidate #Syndivia #advancedcastrationresistantprostatecancer #CRPC #mCRPC #multiplemyeloma #multiplemyelomaADC #prostatecancer #B7H3targetedADC #Hansoh #osteosarcoma #ESMO #GeminiMabconjugationtechnology
zurl.co/8KpGz

About Half of mCRPC Patients with BRCA1/2 Mutations Receive PARP Inhibitors Patients with mCRPC who are covered by commercial insurance are less likely to receive PARP inhibitors than those covered by government-issued insurance, researchers reported.

In the US, only around half of men with #mCRPC harboring BRCA1/2 alterations receive a PARP inhibitor. Published by @jamanetworkopen.com.

https://bit.ly/3W6WCG9

#pcsm #prostatecancer #gucsm

💥Integration of #LiquidBiopsy into a diagnostic algorithm
enables broader access to BRCA1/2 stratification and supports timely PARP inhibitor therapy

This #consensus aims to improve diagnostic consistency and clinical outcomes in #mCRPC management

journals.sagepub.com/share/HUFFX4...

#pcsm

Blue Earth Therapeutics Unveils Dose Intensification Findings for mCRPC Treatment Discover how Blue Earth Therapeutics' new data could revolutionize the treatment of metastatic prostate cancer through dose intensification workflows.

Blue Earth Therapeutics Unveils Dose Intensification Findings for mCRPC Treatment #USA #Oxford #Blue_Earth_Therapeutics #Lutetium177Lu #mCRPC

🧰 Discover Metastatic Castrate Resistant Prostate Cancer Tool in ONCOassist!

Have you tried the mCRPC Tool yet? Designed to support oncology professionals treating metastatic castration-resistant prostate cancer.

🔗 Click here to access the tool now 👉 bit.ly/ONCOassist_mCRPC_Tool

#Oncology #mCRPC